In this composite image, a human nerve cell derived from a patient with Rett syndrome shows significantly decreased levels of KCC2 compared to a control cell.
Image: Gong Chen lab, Penn State University
Penn State scientists have discovered a novel drug target and have rescued functional deficits in human nerve cells derived from patients with Rett Syndrome, a severe form of autism-spectrum disorder. The research, led by Gong Chen, professor of biology and the Verne M. Willaman Chair in Life Sciences at Penn State, could lead to a new treatment for Rett Syndrome and other forms of autism-spectrum disorders. A paper describing the research was published on Jan. 4, 2016, in the online Early Edition of the journal Proceedings of the National Academy of Sciences.
“The most exciting part of this research is that it directly uses human neurons that originated from Rett Syndrome patients as a clinically-relevant disease model to investigate the underlying mechanism,” said Chen. “Therefore, the new drug target discovered in this study might have direct clinical implication in the treatment of Rett Syndrome and potentially for other autism-spectrum disorders as well.”
The researchers differentiated stem cells derived from the skin cells of patients with Rett Syndrome into nerve cells that could be studied in the laboratory. These nerve cells carry a mutation in the gene MECP2, and such gene mutations are believed to be the cause of most cases of Rett Syndrome. The researchers discovered that these nerve cells lacked an important molecule, KCC2, that is critical to normal nerve cell function and brain development.
“KCC2 controls the function of the neurotransmitter GABA at a critical time during early brain development,” Chen said. “Interestingly, when we put KCC2 back into Rett neurons, the GABA function returns to normal. We therefore think that increasing KCC2 function in individuals with Rett Syndrome may lead to a potential new treatment.”
The researchers also showed that treating diseased nerve cells with insulin-like growth factor 1 (IGF1) elevated the level of KCC2 and corrected the function of the GABA neurotransmitter. IGF1 is a molecule that has been shown to alleviate symptoms in a mouse model of Rett Syndrome and is the subject of an ongoing phase-2 clinical trial for the treatment of the disease in humans.
“The finding that IGF1 can rescue the impaired KCC2 level in Rett neurons is important not only because it provides an explanation for the action of IGF1,” said Xin Tang, a graduate student in Chen’s Lab and the first-listed author of the paper, “but also because it opens the possibility of finding more small molecules that can act on KCC2 to treat Rett syndrome and other autism spectrum disorders.”
Read more:Â Discovery of a new drug target could lead to novel treatment for severe autism
The Latest on: Autism-spectrum disorder
via Google News
The Latest on: Autism-spectrum disorder
- Camp Wonderland offers theater, arts experience to children with autism spectrum disorderon August 3, 2022 at 2:01 am
A longstanding program created by The Augusta Players offers children with autism spectrum disorder 10 days of theater and arts at Camp Wonderland.
- Children perform in Camp Wonderland theater show for children with autism spectrum disorderon August 3, 2022 at 2:01 am
Camp Wonderland offers youngsters with autism spectrum disorder training in art, music and drama over the summer. Here's a look at their performance.
- Traffic Stop Event for Drivers With Autism Coming to Eastern Conn.on August 2, 2022 at 2:39 pm
Waterford and Groton Police Departments are working with Southern Connecticut State University to host a mock traffic stop event for drivers with Autism Spectrum Disorder. For the last two years, SCSU ...
- A New Learning Method Could Help People With Autism Improve Visual Perception Capabilitieson August 1, 2022 at 2:29 pm
A newly proposed learning method for those on the autism spectrum accelerates the learning process and can help to improve visual perception.
- Autism Spectrum Disorders Market is expected to show positive growth, during the forecast period of 2019 to 2032, DelveInsighton August 1, 2022 at 11:07 am
The MarketWatch News Department was not involved in the creation of this content. Aug 01, 2022 (AB Digital via COMTEX) -- The Autism Spectrum Disorders market report provides an edge while developing ...
- New evidence hints at the role of gut microbiota in autistic spectrum disorderon July 29, 2022 at 7:38 am
Autism spectrum disorder (ASD) is a neurological and developmental condition that affects how humans communicate, learn new things and behave. Symptoms of ASD can include difficulties in interacting ...
- Your Eyes Could Reveal if You Have ADHD or Autismon July 29, 2022 at 4:24 am
The eyes might disclose everything when it comes to ADHD and ASD. It’s often said that "the eyes tell it all." According to a recent study from Flinders University and the University of South ...
- At the Crossroads of Trauma and Autismon July 28, 2022 at 8:21 am
Up to 72 percent of adults with autism may have severe trauma histories. It is hard to find research on the lives of adults with autism before 2000 and virtually impossible to find research on adult ...
- Autism Spectrum Disorder Diagnostics Market Global Outlook, and Forecast 2022 To 2028.on July 26, 2022 at 11:02 am
The " Autism Spectrum Disorder Diagnostics market research report " provides a holistic analysis, market size and forecast from year to year, trends, growth drivers, and challenges, as well as vendor ...
- Early diagnosis of autism spectrum disorder makes a difference for patients and familieson July 26, 2022 at 8:56 am
While screening techniques for ASD have improved, diagnosis and cause are still far from straightforward. On WGCU's Gulf Coast Life, a discussion about the early detection.
via Bing News
